Scarica l'app Stockscreener
3.73
2.61%
-0.10
Pre-mercato:
3.76
0.03
+0.80%
Plus Therapeutics Inc Borsa (PSTV) Ultime notizie
Plus Therapeutics Inc (PSTV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Plus Therapeutics Inc (PSTV) Cash Flow - TradingKey
Plus Therapeutics Inc (PSTV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PSTV|Plus Therapeutics Inc|Price:3.770|Chg%:-0.060 - TradingKey
Plus Therapeutics Inc (PSTV) Income Statement - TradingKey
Plus Therapeutics Inc (PSTV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PSTV|Plus Therapeutics Inc|Price:3.830|Chg%:+0.050 - TradingKey
PLUS THERAPEUTICS Inc. (PSTV) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Plus Therapeutics Inc (PSTV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Plus Therapeutics Inc. R (XMP1.DU) stock price, news, quote and history - Yahoo Finance UK
Plus Therapeutics Inc (PSTV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Plus Therapeutics, Inc. (PSTV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Plus Therapeutics secures regional coverage for... - Pluang
Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - The Manila Times
CNSide Diagnostics signs coverage deal with Medical Mutual - Investing.com
CNSide Diagnostics signs coverage deal with Medical Mutual By Investing.com - Investing.com Canada
Plus Therapeutics Secures Regional Coverage Agreement with - GlobeNewswire
Plus Therapeutics Inc. R (XMP1.DU) valuation measures and financial statistics - Yahoo Finance UK
PLUS THERAPEUTICS INC (PSTV) Stock Chart - ChartMill
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform - Sahm
Plus Therapeutics partners with GTC on CSF diagnostic platform - Investing.com UK
Plus Therapeutics partners with GTC on CSF diagnostic platform By Investing.com - Investing.com Nigeria
Plus Therapeutics (PSTV) Forms Partnership for Advanced Biomarker Profiling - GuruFocus
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring - Sahm
NCCN updates guidelines for leptomeningeal metastases diagnosis - Investing.com UK
Plus Therapeutics (PSTV) Updates NCCN Guidelines for CNS Cancers - GuruFocus
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines - GlobeNewswire
Guidelines call for spinal-fluid checks every 4–8 weeks during therapy - Stock Titan
PLUS THERAPEUTICS (PSTV) Surges 7%: Biotech Momentum Testing Key ResistanceFair Value Gap - DonanımHaber
Plus Therapeutics subsidiary enrolls in Medicare program - Investing.com
PSTV Should I Buy - Intellectia AI
PLUS THERAPEUTICS Inc. (PSTV) Q1 2026 Earnings: Wider Loss Per Share Overshadows Clinical ProgressProfit Growth Outlook - dars.gov.et
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hawkins Richard J - Moomoo
Plus Therapeutics (PSTV) CEO gains 16,439 shares from RSU vesting - Stock Titan
PLUS Therapeutics (PSTV) director converts 922 RSUs into common stock - Stock Titan
Plus Therapeutics (NASDAQ: PSTV) director gains 922 shares via RSU vesting - Stock Titan
PLUS Therapeutics (PSTV) CFO converts RSUs into 2,985 common shares - Stock Titan
[Form 4] PLUS THERAPEUTICS, INC. Insider Trading Activity - Stock Titan
Plus Therapeutics provides mid-year business update including corporate rebranding - MSN
Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY - Investing.com UK
Plus Therapeutics Advances REYOBIQ Clinical Trials and Manufacturing Progress - marketscreener.com
Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV) - Yahoo Finance
Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY By Investing.com - Investing.com South Africa
Plus Therapeutics to Rebrand as Cerenome, Affirm 2026 Guidance and Report CNSide Commercial Progress - Quiver Quantitative
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding - GlobeNewswire
Price to earnings forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Enterprise value to EBITDA forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Enterprise value to EBIT forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Price to sales forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Enterprise value to revenue forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Plus Therapeutics, Inc.(NasdaqCM: PSTV) added to Russell 3000E Index - marketscreener.com
Plus Therapeutics, Inc.(NasdaqCM: PSTV) added to Russell 3000E Growth Benchmark - marketscreener.com
Plus Therapeutics, Inc.(NasdaqCM: PSTV) added to Russell Microcap Index - marketscreener.com
PLUS THERAPEUTICS (PSTV) Faces Mild Pressure Near Key Support ZoneEase of Movement - dars.gov.et
Plus Therapeutics, Inc. Actuals & Estimates (DUS:XMP1) - TradingView
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):